Recurrent Ovarian Clear Cell Adenocarcinoma
9 clinical trials · Condition
◉ Watch Recurrent Ovarian Clear Cell Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800) | National Cancer Institute (NCI) | 2021-06-10 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (NCT04092270) | National Cancer Institute (NCI) | 2020-05-07 |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (NCT03348631) | National Cancer Institute (NCI) | 2019-05-01 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707) | National Cancer Institute (NCI) | 2017-06-23 |
Track Recurrent Ovarian Clear Cell Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.